IMTX Stock Analysis: Buy, Sell, or Hold?
IMTX - Immatics N.V. Ordinary Shares
$9.02
0.36 (4.16%)
▲
5d:
+4.52%
30d:
-9.35%
90d:
-16.4%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 12, 2026
8d
Get Alerted When IMTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMTX is currently trading at $9.02, which is considered slightly low relative to its 30-day fair value range of $9.12 to $9.94.
Technical Outlook: Technically, IMTX is in a downtrend. Immediate support is located at $8.17, while resistance sits at $9.57. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: IMTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $17.87 (+98.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMTX is in a downtrend. Immediate support is located at $8.17, while resistance sits at $9.57. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: IMTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $17.87 (+98.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$9.12 -
$9.94
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.2%)
- BULLISH: Trading 98.1% below Wall St target ($17.87)
Trading Range Analysis
30-Day Trading Range
$9.12 -
$9.94
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$8.17
Resistance Level
$9.57
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.74
Wall Street Target
$17.87
(+98.1%)
Revenue Growth (YoY)
-59.0%
Share & Embed Analysis
Last updated: August 03, 2026 5:07 PM ET
Data refreshes hourly during market hours. Next update: 6:07 PM
Data refreshes hourly during market hours. Next update: 6:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
